• Placement to raise A$2.4M and 1-for-4 entitlement offer to raise A$4.1M
• Proceeds to fund inventory, sales & marketing, product development, working capital, and debt repayment
• Existing major shareholder C2 Ventures to participate in full and partially sub-underwrite the entitlement offer

Cardiex Ltd (ASX: CDX) announced an equity raising of approximately A$6.5 million to fund the company's growth initiatives. The equity raising comprises a placement to raise A$2.4 million and a 1-for-4 pro-rata non-renounceable entitlement offer to raise A$4.1 million. The offer price is A$0.04 per new share, representing a 20% discount to the last close price. Existing major shareholder C2 Ventures will participate in full under the entitlement offer and also partially sub-underwrite the entitlement offer for approximately A$1.2 million. The proceeds from the equity raising will be used for inventory build-up (A$1 million), sales and marketing activities (A$1.5 million), further research and development (A$1 million), working capital requirements (A$2 million), and repayment of debt (A$0.5 million). The company is also anticipating an additional A$1.5 million R&D tax refund in or around October 2025, which will be used to fully repay the existing R&D finance facility. The equity raising will provide the additional growth capital required for Cardiex to reach cash flow stability and break-even.